Satellos Bioscience Inc (MSCLF)

$0.48 0.00 (N/A)
Market Cap 89.04M
Revenue (ttm) 0.00
Net Income (ttm) -20.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 132,000
Avg Vol 96,018
Day's Range N/A - N/A
Shares Out 185.51M
Stochastic %K 24%
Beta 1.16
Analysts Sell
Price Target $0.86

Company Profile

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an...

Industry: Biotechnology
Sector: Healthcare
Address:
Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
rajbc
rajbc Dec. 10 at 2:54 PM
$MSCLF Calm before the storm. Phase 1 showed Notch Pathway safe to inhibit at AAK1 node using SAT-3247 with good PK, 4-month canine model treatment showed dramatic muscle regeneration, 5 DMD patient phase 1b showed doubling of strength metric (2/3 had dramatic improvement) in 1 month, PII will be global study of 51 kids, first readout Q2 2026, hoping the muscle regeneration works for them GLTA.
0 · Reply
Weightgainclyde
Weightgainclyde Dec. 9 at 8:54 PM
$MSCLF this board is way too quiet. There was a huge victory today. Big milestone reached
1 · Reply
stevetripp
stevetripp Dec. 9 at 7:43 PM
$MSCLF Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy 07:00:00 AM ET, 12/09/2025 - Business Wire
0 · Reply
Florestan
Florestan Dec. 5 at 9:46 AM
$CAPR $MSCLF 1 down, 1 to go.
0 · Reply
Florestan
Florestan Nov. 19 at 2:12 AM
$MSCLF Research confirms muscle stem cell dysfunction impairs polarity and impedes production of myogenic progenitors during fetal development Findings solidify AAK1 as a paradigm shifting drug target to restore muscle repair and regeneration in Duchenne muscular dystrophy https://ir.satellos.com/news/news-details/2025/Satellos-Announces-Publication-in-Nature-Communications-Supporting-its-Novel-Treatment-Approach-for-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
PennyScam
PennyScam Nov. 13 at 9:36 PM
$MSCLF Hello???! Get in there! Crazy K
1 · Reply
PennyScam
PennyScam Nov. 5 at 1:55 AM
$MSCLF Maybe do something like this.……https://www.osler.com/en/insights/updates/exchangeable-share-structures-an-overview/
0 · Reply
Florestan
Florestan Nov. 4 at 9:06 PM
$MSCLF https://musculardystrophynews.com/news/oral-therapy-moves-follow-strong-data-dmd-adults/
2 · Reply
PennyScam
PennyScam Nov. 4 at 3:54 PM
$MSCLF Can you guys merge with INVO or Naya Therapeutics already. Get it done. You guys are taking way too long. Cuckoo Penny
1 · Reply
Florestan
Florestan Nov. 1 at 2:11 AM
$MSCLF fellow watchers, are you a bull, or a bear? What's up? Too quiet for something so revolutionary.
1 · Reply
Latest News on MSCLF
No data available.
rajbc
rajbc Dec. 10 at 2:54 PM
$MSCLF Calm before the storm. Phase 1 showed Notch Pathway safe to inhibit at AAK1 node using SAT-3247 with good PK, 4-month canine model treatment showed dramatic muscle regeneration, 5 DMD patient phase 1b showed doubling of strength metric (2/3 had dramatic improvement) in 1 month, PII will be global study of 51 kids, first readout Q2 2026, hoping the muscle regeneration works for them GLTA.
0 · Reply
Weightgainclyde
Weightgainclyde Dec. 9 at 8:54 PM
$MSCLF this board is way too quiet. There was a huge victory today. Big milestone reached
1 · Reply
stevetripp
stevetripp Dec. 9 at 7:43 PM
$MSCLF Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy 07:00:00 AM ET, 12/09/2025 - Business Wire
0 · Reply
Florestan
Florestan Dec. 5 at 9:46 AM
$CAPR $MSCLF 1 down, 1 to go.
0 · Reply
Florestan
Florestan Nov. 19 at 2:12 AM
$MSCLF Research confirms muscle stem cell dysfunction impairs polarity and impedes production of myogenic progenitors during fetal development Findings solidify AAK1 as a paradigm shifting drug target to restore muscle repair and regeneration in Duchenne muscular dystrophy https://ir.satellos.com/news/news-details/2025/Satellos-Announces-Publication-in-Nature-Communications-Supporting-its-Novel-Treatment-Approach-for-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
PennyScam
PennyScam Nov. 13 at 9:36 PM
$MSCLF Hello???! Get in there! Crazy K
1 · Reply
PennyScam
PennyScam Nov. 5 at 1:55 AM
$MSCLF Maybe do something like this.……https://www.osler.com/en/insights/updates/exchangeable-share-structures-an-overview/
0 · Reply
Florestan
Florestan Nov. 4 at 9:06 PM
$MSCLF https://musculardystrophynews.com/news/oral-therapy-moves-follow-strong-data-dmd-adults/
2 · Reply
PennyScam
PennyScam Nov. 4 at 3:54 PM
$MSCLF Can you guys merge with INVO or Naya Therapeutics already. Get it done. You guys are taking way too long. Cuckoo Penny
1 · Reply
Florestan
Florestan Nov. 1 at 2:11 AM
$MSCLF fellow watchers, are you a bull, or a bear? What's up? Too quiet for something so revolutionary.
1 · Reply
Florestan
Florestan Oct. 28 at 4:32 PM
$MSCLF seeing a number of new watchers here, introduce yourselves friends, don't stay too quiet 😎
0 · Reply
Florestan
Florestan Oct. 21 at 3:22 PM
$MSCLF - First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled - 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers - Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter - Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open the study in the U.S., subject to regulatory and clinical site approvals https://ir.satellos.com/news/news-details/2025/Satellos-Announces-First-Adult-Patient-Dosed-in-LT-001-an-Open-Label-Long-Term-Follow-Up-Study-of-SAT-3247-in-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
Florestan
Florestan Oct. 21 at 3:21 PM
$MSCLF - First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled - 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers - Results following initial 3 months of treatment anticipated in early 2026, quarterly thereafter - Planning underway to broaden LT-001 study protocol to enroll new adult patients in Australia and open the study in the U.S., subject to regulatory and clinical site approvals https://ir.satellos.com/news/news-details/2025/Satellos-Announces-First-Adult-Patient-Dosed-in-LT-001-an-Open-Label-Long-Term-Follow-Up-Study-of-SAT-3247-in-Duchenne-Muscular-Dystrophy/default.aspx
0 · Reply
Florestan
Florestan Oct. 13 at 5:07 PM
$MSCLF https://www.biospace.com/press-releases/satellos-announces-new-data-further-demonstrating-safety-tolerability-and-functional-impact-of-sat-3247-in-first-in-human-trial-of-adults-with-duchenne-muscular-dystrophy
0 · Reply
theoptionsplug
theoptionsplug Oct. 10 at 6:58 AM
FRIDAY THINGS TO WATCH: 🏦9:45AM: Chicago Fed President Austan Goolsbee gives opening remarks and moderates a panel at the 19th Annual Community Bankers Symposium. 📈10:00AM: Economists watch the preliminary October University of Michigan survey for updates on consumer sentiment and inflation expectations. 📊2:00PM: September Monthly U.S. federal budget will be released 🎮 $EA launches Battlefield 6 on PS5, Xbox Series X|S, and PC with a global simultaneous release. Set in 2027, it depicts a conflict between a fractured NATO and the private military group Pax Armata. 🏀NBA preseason games in Macau’s Venetian Arena feature the Brooklyn Nets vs. Phoenix Suns, boosting The Venetian Macau owned by $SCHYY (a majority subsidiary of $LVS). 🧬 $CRSP, $DTIL, and $MSCLF present at the World Muscle Society Congress.
0 · Reply
fullmetalll
fullmetalll Oct. 8 at 7:03 AM
$MSCLF who the watchers here? We wait
0 · Reply
Florestan
Florestan Oct. 7 at 2:34 PM
$MSCLF highly undervalued for real
0 · Reply
fullmetalll
fullmetalll Oct. 7 at 2:24 PM
$MSCLF Today 4% up
0 · Reply
fullmetalll
fullmetalll Oct. 7 at 2:20 PM
$MSCLF Slow, Volume 34.5K, lets go
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 9:07 PM
$MSCLF The thing here looks like it is completely undervalued. Hardly anyone knows the stock. How should it be known? How should sales come in here? Maybe they can be taken over. Let's go
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 8:15 PM
$MSCLF 116 watchers, what a Joke.
1 · Reply
fullmetalll
fullmetalll Oct. 6 at 7:32 PM
$MSCLF What's this? Hardly any watchers, and Phase 2 is in. Surely there should be at least a 300% upside? There are no watchers. Very, very bullish.
1 · Reply